NCT04274023

Study on TSR-042 in Advanced Clear Cell Sarcoma

Phase II Study on TSR-042 in Advanced Clear Cell Sarcoma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Italian Sarcoma Group · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase II,single arm study designed to explore the activity of TSR-042, an immunotherapy agent, in patients with a diagnosis of advanced or metastatic clear cell sarcoma (CCS).

Detailed description

Phase II, single arm, not randomized, European multicentric study designed to explore the activity of TSR-042, a human monoclonal anti-PD-1 inhibitor, in a population of patients with a diagnosis of advanced/metastatic clear cell sarcoma (CCS).

Conditions

• Sarcoma, Clear Cell

Interventions

Type	Name	Description
DRUG	TSR-042	TSR-042 is an IgG4 humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2.

Timeline

• Start date: 2024-01-29
• Primary completion: 2024-01-29
• Completion: 2024-01-29
• First posted: 2020-02-18
• Last updated: 2024-02-01

Locations

1 site across 1 country: Italy